Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Formulation exports drive Zydus Cadila's sales up 25% in Q1

This article was originally published in Scrip

Executive Summary

Zydus Cadilahas reported a 25% increase in total income to Rs7.14 billion ($168.9 million) for the first quarter ended June 30th, compared with the same period last year. This was led by strong growth in formulation exports. Net profits increased by 21% to Rs900 million and formulation exports increased by 60%. The US and French businesses reported sales growth of 36%. Zydus launched venlafaxine hydrochloride tablets in the US and received FDAapproval for pravastatin sodium tablets and benazepril tablets during the quarter. Tentative FDA approvals were given to escitalopram oxalate tablets, losartan potassium and hydrochlorothiazide tablets and anastrozole tablets. Zydus has filed 79 ANDAs and 59 drug master files so far. The company expanded its global presence and acquired Laboratorios Combix in Spain and a 70% stake in Simayla Pharmaceuticals of South Africa during the quarter.

Topics

UsernamePublicRestriction

Register

SC006814

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel